DPP4 and Hyperglycemia: DPP4/CD26 inhibitors (gliptins) have found application in the treatment of hyperglycaemia since they inhibit the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) hormones [168].